Grant: Catalyst Grant: Innovation in HIV Vaccine and HIV Cure Research
Centre hospitalier de l'Université de Montréal (CHUM)
$100,000.00
Identification of Naturally-Occurring anti-HIV-1 Neutralizing Molecules from a Cohort of Highly-HIV-1-Exposed Seronegative Individuals
EF 2012-13
Résumé
Worldwide, it is estimated that 34 million people live with human immunodeficiency virus (HIV). In 2010 alone around 2.7 million became newly infected with HIV and 1,8 million died from AIDS. In Canada, it is estimated that 65,000 people are living with HIV/AIDS and thousands are newly infected every year. In the absence of effective vaccines against HIV and with therapies aimed at HIV eradication remaining a far-fetched goal, new approaches to fight HIV infection are warranted. Perhaps new strategies to fight HIV-1 infection could be learned from a group of individuals that remain HIV-1-negative despite being highly exposed to HIV-1. So far it is still not fully understood how these individuals, referred as Highly Exposed to HIV-1 but Persistently Seronegative (HEPS), succeed to avoid HIV-1 transmission. Understanding the basis of their HIV-1 resistance and identifying and characterizing potential anti-HIV-1 molecules, including broadly neutralizing antibodies, from these healthy HIV-1-uninfected-individuals might help direct efforts in next-generation anti-HIV-1 entry inhibitors, vaccine and microbicides design.
Programme
Catalyst Grant: Innovation in HIV Vaccine and HIV Cure Research
Emplacement
Quebec, Canada
Type de bénéficiaire
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
275305
Name
Finzi Andrés
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
HIV Vaccine and Cure Research
Projecttitle
Identification of Naturally-Occurring anti-HIV-1 Neutralizing Molecules from a Cohort of Highly-HIV-1-Exposed Seronegative Individuals
Programtype2
Operating Grants
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Innovation in HIV Vaccine and HIV Cure Research
Keyworddelim
Biochemical Fractionation; Broadly Neutralizing Antibodies; Ccr5; Cd4; Cxcr4; Envelope Glycoproteins; Gp120; Gp41; Hiv-1; Small Molecules Inhibitors; Structure Of Neutralizing Abs In Complex With Hiv-1 Env; Viral Fusion
Abstract
Worldwide, it is estimated that 34 million people live with human immunodeficiency virus (HIV). In 2010 alone around 2.7 million became newly infected with HIV and 1,8 million died from AIDS. In Canada, it is estimated that 65,000 people are living with HIV/AIDS and thousands are newly infected every year. In the absence of effective vaccines against HIV and with therapies aimed at HIV eradication remaining a far-fetched goal, new approaches to fight HIV infection are warranted. Perhaps new strategies to fight HIV-1 infection could be learned from a group of individuals that remain HIV-1-negative despite being highly exposed to HIV-1. So far it is still not fully understood how these individuals, referred as Highly Exposed to HIV-1 but Persistently Seronegative (HEPS), succeed to avoid HIV-1 transmission. Understanding the basis of their HIV-1 resistance and identifying and characterizing potential anti-HIV-1 molecules, including broadly neutralizing antibodies, from these healthy HIV-1-uninfected-individuals might help direct efforts in next-generation anti-HIV-1 entry inhibitors, vaccine and microbicides design.
Competitiondate
201211
Approvedterm2
1 yr 0 mth
Pinamesdelim
Finzi, Andrés
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
